RLMD News and Press, Relmada Therapeutics Inc. From 06/15/21

Relmada Therapeutics to Present Data at the College on Problems of Drug Dependence 83rd Annual Scientific Meeting PR Newswire NEW YORK , June 15, 2021 /PRNewswire/ -- Relmada Therapeutics, Inc. (Nasdaq: RLMD), a late-stage biotechnology company addressi...

Relmada Therapeutics Announces Participation in Goldman Sachs 42nd Annual Global Healthcare Conference PR Newswire NEW YORK , June 7, 2021 /PRNewswire/ -- Relmada Therapeutics, Inc. (Nasdaq: RLMD), a late-stage biotechnology company addressing diseases of th...

Relmada Therapeutics Announces Participation in Jefferies Virtual Healthcare Conference PR Newswire NEW YORK , June 1, 2021 /PRNewswire/ -- Relmada Therapeutics, Inc. (Nasdaq: RLMD), a late-stage biotechnology company addressing diseases of the central nervo...

Relmada Therapeutics Announces Oral Poster Presentation on REL-1017 at 2021 American Society of Clinical Psychopharmacology Annual Meeting PR Newswire NEW YORK , May 26, 2021 /PRNewswire/ -- Relmada Therapeutics, Inc. (Nasdaq: RLMD), a late-stage biotechnolo...

Relmada Therapeutics, Inc. (RLMD) Q1 2021 Results Earnings Conference Call May 12, 2021, 04:30 PM ET Company Participants Tim McCarthy - LifeSci Advisors Sergio Traversa - Chief Executive Officer Chuck Ence - Chief Accounting and Compliance Officer Conference Call Participants Andrew Tsai - J...

Relmada Therapeutics (RLMD): Q1 GAAP EPS of -$1.34 beats by $0.06.Cash, cash equivalents, and short-term investments of $102.7M.Press Release For further details see: Relmada Therapeutics EPS beats by $0.06

Relmada Therapeutics Provides Corporate Update and Reports First Quarter 2021 Financial Results PR Newswire NEW YORK , May 12, 2021 /PRNewswire/ -- Relmada Therapeutics, Inc. (Nasdaq: RLMD), a late-stage biotechnology company addressing diseases of the central ne...

Relmada Therapeutics to Report First Quarter 2021 Financial Results and Host Conference Call and Webcast on May 12, 2021 PR Newswire NEW YORK , May 6, 2021 /PRNewswire/ -- Relmada Therapeutics, Inc. (Nasdaq: RLMD), a late-stage biotechnology company addressi...

Relmada Therapeutics Announces Poster Presentations at the American Psychiatric Association Annual Meeting 2021 PR Newswire NEW YORK , May 1, 2021 /PRNewswire/ -- Relmada Therapeutics, Inc. (Nasdaq: RLMD), a late-stage biotechnology company addressing diseas...

Relmada Therapeutics Announces Poster Presentations at the 2021 Society of Biological Psychiatry Annual Meeting PR Newswire NEW YORK , April 29, 2021 /PRNewswire/ -- Relmada Therapeutics, Inc. (Nasdaq: RLMD), a late-stage biotechnology company addressing dis...